Literature DB >> 17476865

Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass.

Janani Arun1, Niraj Jhala, Audrey J Lazenby, Ronald Clements, Gary A Abrams.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that can progress to cirrhosis and hepatocellular cancer. The most progressive form of NAFLD is nonalcoholic steatohepatitis (NASH). Currently, the only method to diagnose NASH is with a liver biopsy; however. sampling error may limit diagnostic accuracy. We investigated the discordance of paired liver biopsies in individuals undergoing gastric bypass.
METHODS: Two liver biopsies, composite size of > or = 25 mm and > or = 8 portal tracts (PTs), were obtained from the left lobe in 31 subjects. Group 1 included specimens at least 15 mm in length with > or = 4 PTs compared to a second biopsy of at least 10 mm and > or = 4 PTs (Group 2).
RESULTS: The mean specimen size (number of PTs) for group 1 was 20.4 +/- 4.2 mm (11.7 +/- 5.5 PTs) and group 2 was 16.1 +/- 5.3 mm (8.2 +/- 4.1 PTs). Prevalence of NASH was 26% in Group 1 and 32% in Group 2. Sampling discordance was greatest for portal fibrosis (26%), followed by zone 3 fibrosis (13%) and ballooning degeneration (3%). The negative predictive values from Group 1 liver biopsies for NASH and portal fibrosis were only 83% and 67%, respectively.
CONCLUSIONS: The results demonstrate that significant sampling variability exists in class 2 and 3 obese individuals undergoing screening liver biopsies for NAFLD. The degree and histopathological discordance is dependent upon zonal location and types of injury. Nevertheless, a 25-mm biopsy specimen without zone 3 cellular ballooning or fibrosis appears adequate to exclude the diagnosis of NASH.

Entities:  

Mesh:

Year:  2007        PMID: 17476865     DOI: 10.1007/s11695-007-9041-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  24 in total

1.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

4.  Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters.

Authors:  Anna Maria Wolf; Bernd Busch; Hans Werner Kuhlmann; Ulrike Beisiegel
Journal:  Obes Surg       Date:  2005-02       Impact factor: 4.129

5.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.

Authors:  Guido Colloredo; Maria Guido; Aurelio Sonzogni; Gioacchino Leandro
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

9.  Years of life lost due to obesity.

Authors:  Kevin R Fontaine; David T Redden; Chenxi Wang; Andrew O Westfall; David B Allison
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

View more
  13 in total

1.  The inhomogeneous distribution of liver function: possible impact on the prediction of post-operative remnant liver function.

Authors:  Henrik Nilsson; Silja Karlgren; Lennart Blomqvist; Eduard Jonas
Journal:  HPB (Oxford)       Date:  2014-10-09       Impact factor: 3.647

Review 2.  The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.

Authors:  Mangesh R Pagadala; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2012-06-27       Impact factor: 6.126

3.  Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1.

Authors:  Angel Carazo; Josefa León; Jorge Casado; Ana Gila; Sergio Delgado; Ana Martín; Laura Sanjuan; Trinidad Caballero; Jose Antonio Muñoz; Rosa Quiles; Angeles Ruiz-Extremera; Luis Miguel Alcázar; Javier Salmerón
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

Review 4.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

5.  Correlations of laparoscopy with histology and laboratory studies on liver diseases in bariatric patients.

Authors:  Chong-Chi Chiu; Wei-Jei Lee; Weu Wang; Yi-Chih Lee; Ming-Te Huang
Journal:  Obes Surg       Date:  2007-12-28       Impact factor: 4.129

6.  Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis.

Authors:  H Nilsson; L Blomqvist; L Douglas; A Nordell; I Janczewska; E Näslund; E Jonas
Journal:  Br J Radiol       Date:  2013-02-12       Impact factor: 3.039

7.  Bariatric Surgery to Correct Morbid Obesity Also Ameliorates Atherosclerosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Yong Wang; Cuihua Zhang
Journal:  Am J Biomed Sci       Date:  2009-01-01

8.  Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients.

Authors:  Daniella Braz Parente; Fernando Fernandes Paiva; Jaime Araújo Oliveira Neto; Lilian Machado-Silva; Fatima Aparecida Ferreira Figueiredo; Valeria Lanzoni; Carlos Frederico Ferreira Campos; Pedro Emmanuel Alvarenga Americano do Brasil; Marilia de Brito Gomes; Renata de Mello Perez; Rosana Souza Rodrigues
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 9.  Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease.

Authors:  Linda A Ban; Nicholas A Shackel; Susan V McLennan
Journal:  Int J Mol Sci       Date:  2016-03-14       Impact factor: 5.923

10.  Development of a novel rat model of heterogeneous hepatic injury by injection with colchicine via the splenic vein.

Authors:  Yan-Yan Zhang; Chao-Xu Zhang; Yu Li; Xuan Jiang; Yong-Fang Wang; Yang Sun; Jun Wang; Wan-Ying Ji; Yi Liu
Journal:  World J Gastroenterol       Date:  2018-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.